Is Fidelity Medical Equipment the Ultimate "Forever Fund" for Health Care Investors?

Federal spending cuts in 2025 stripped more than $1 trillion from U.S. health programs and tariffs (potentially up to 250% on non-U.S. drugs/devices) cloud the sector, yet the Health Care Select Sector ETF (XLV) is still up ~13% YTD versus the S&P 500's ~17%. The Fidelity Select Medical Technology and Devices Portfolio (FSMEX) lagged, down 2.5% YTD, but holds 64 device companies including Boston Scientific (12% weight) — which reported +18% net sales in 2024 and +20% net sales in the most recent 2025 quarter — and income leaders Abbott and Stryker; FSMEX paid $5.96/share in 2024 (≈9% yield for holders at start of year) and $4.67 so far in 2025 (≈7.5% yield). Management argues secular demographics, attractive distributions, and potential policy relief around the 2026 election could improve the sector outlook, while FSMEX’s long-term track record shows ~13% annualized returns since 1998 versus the S&P 500’s 8.9%.

Analysis

Market structure: Domestic medical-device manufacturers and dividend-rich large caps (e.g., BSX, ABT, SYK) are the primary beneficiaries of tariff-driven reshoring and inelastic elderly healthcare demand; small, import-dependent device and mid/small-cap biotech firms face immediate margin compression if a broad tariff is enacted. Tariffs and federal reimbursement cuts compress supply of low-cost imports, improving pricing power for US-made devices and consumables while increasing input-cost pass-through into hospital budgets over 6–18 months.

Risk assessment: Tail risks include a Supreme Court or administrative decision upholding broad 250% tariffs (catastrophic for importers) or Congress failing to extend subsidies pre-midterms (reducing insured demand); either could trigger >20% downside for exposed names within weeks. Near-term (0–3 months) volatility will cluster around tariff rulings and midterm legislative windows; long-term (1–3 years) demographic demand likely offsets some policy shocks, but depends on reimbursement and FX-driven margin recovery.

Trade implications: Favor concentrated long exposure to FSMEX (medical-device basket) and high-quality device names (BSX, ABT, SYK) while shorting smaller, globally outsourced device peers; use calendar/options to harvest yield and hedge policy risk. Cross-asset: expect higher healthcare equity correlation with Treasuries if investors rotate to income — a 10–50bp move in 10y yields could swing valuation multiples by 3–7% on income names.

Contrarian angles: The market may be overstating permanent tariff damage — carve-outs and targeted dispensations are plausible (timeline: 0–9 months), which would cause rapid mean reversion for beaten-up funds like FSMEX. Historical parallels (post-sequestration 2013) show temporary policy shocks often produced 12–24 month buying windows; unintended consequence: accelerated capex and domestic-supply beneficiaries emerge sooner than consensus expects.

Key Decisions for Investors

• Establish a 2–3% portfolio long in Fidelity Select Medical Technology & Devices (FSMEX) within 4 weeks; target 12–18 month total return +15–25%, place a stop-loss at -12% or reduce if distributions fall below $3.50 annualized.
• Initiate a 1.5% long position in Boston Scientific (BSX) via outright shares or Jan 2027 LEAP calls ~15% OTM to capture device share gains; trim if quarterly organic growth drops below +5% YoY or if margin guidance falls >200bps.
• Run a relative-value pair: long BSX (1.5%) vs short Medtronic (MDT) (1.5%) to express domestic-device premium; unwind if relative spread (BSX/MDT) narrows to historical median or exceeds 8% adverse move within 90 days.
• Use options to generate yield and hedge: sell 60-day cash-secured puts on Abbott (ABT) at ~5% OTM to collect premium or acquire a 6-month protective put (FSMEX) at ~7–10% OTM if initiating FSMEX exposure; adjust sizes to keep portfolio delta neutral.
• Trigger-based allocation: if within 90 days Congress extends insurance subsidies or the administration grants tariff carve-outs to >25 named healthcare firms, add incremental 2–4% to device/large-cap healthcare (allocate pro rata to FSMEX, BSX, ABT).